Table 2.
Lung function | Association | |
---|---|---|
β (95%CI) | Mediation (%)a | |
FEV1 | ||
PA-Moderate | ||
Total | 0.085 (0.049, 0.121) | |
Direct | 0.077 (0.041, 0.113) | |
Indirect via CRP | 0.009 (−0.001, 0.017) | 10.05 |
PA-High | ||
Total | 0.149 (0.106, 0.193) | |
Direct | 0.130 (0.086, 0.174) | |
Indirect via CRP | 0.019 (0.010, 0.029) | 12.99b |
FVC | ||
PA-Moderate | ||
Total | 0.131 (0.086, 0.176) | |
Direct | 0.123(0.078, 0.168) | |
Indirect via CRP | 0.009 (−0.001, 0.017) | 6.58 |
PA-High | ||
Total | 0.207 (0.153, 0.262) | |
Direct | 0.188 (0.133,0.243) | |
Indirect via CRP | 0.020 (0.010, 0.029) | 9.42b |
CRP C-reactive protein, CI Confidence interval, FEV1 Forced expiratory volume in one second, FVC Forced vital capacity, PA Physical activity; β: regression coefficient
Models were adjusted for age, sex, education level, cigarette smoking, alcohol drinking, body mass index, cardiovascular diseases (angina, congestive heart failure and stroke), chronic lung diseases, cancer and dementia
Total effect is the effect of PA on lung function without CRP; direct effect is the effect of PA on lung function when controlling for CRP; indirect effect is the effect of PA on lung function via CRP
aMediation (%) is calculated by indirect effect/total effect ×100
bP<0.001